Tue 1/28/2020 15:36 ET
S&P 5003283.3440.061.22%BANKS492.635.911.20%OIL53.620.480.90%BITCOIN9059.80151.301.67%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Athersys - ATHX   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ATHX
From: blacksheep (Rep: 332) reply to robotinvestorDate: 12/18/2017 08:01
Forum: Athersys - Msg #1039Thread #673966378 (Rec: 0)
Re: Tiny stem cell companies close in on major heart disease goals
Bill Berkrot

NEW YORK (Reuters) - The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011.

Vials of MPC-150-IM, Mesoblast's stem cell product, are seen in this undated handout photo received December 14, 2017. Mesoblast/Handout via REUTERS
But two small companies, Athersys Inc and Mesoblast Ltd, are beginning final stage trials in hundreds of patients that they - along with loyal investors - say could change the course of devastating stroke and heart failure.

Both have overcome major hurdles to manufacturing stem cell treatments on a large scale that are off-the-shelf products derived from healthy donor bone marrow and do not face immune system rejection issues.

Cleveland-based Athersys, with a market value of about $200 million, demonstrated evidence in a midstage trial that its therapy may be able to expand the emergency treatment window for major strokes to up to 36 hours, compared with about four hours with current drugs, potentially allowing many more patients to avoid crippling disabilities.

Australia’s Mesoblast, with a market value of about $500 million, is attempting to alter advanced heart failure, a leading cause of hospitalizations and deaths and an enormous cost burden.

They are among the farthest along in the stem cell industry at a time when Wall Street investors have focused on potentially big payoffs from immune-system based cancer therapies and rare disease treatments.

Perception of the field has also been hurt by unscrupulous actors selling unapproved, possibly unsterile cell therapies for everything from cancer to lung disease and ALS, prompting a U.S. crackdown this past summer.

“The market tends to test these companies sometimes to the brink,” said Tom Dobell, who manages a fund for U.K.-based M&G Investment Management that specializes in supporting promising companies during difficult periods. “We’re comfortable that the progress that’s going on is going to be worth it.”

M&G is a long-time holder of Mesoblast, with about a 15 percent stake, and Athersys, with about 4 percent.

Athersys’s experimental Multistem treatment was one of the first companies to be designated by the U.S. Food and Drug Administration as a promising cell-based therapy with potential to address unmet needs for serious or life threatening conditions, potentially easing the approval process.

FDA Commissioner Scott Gottlieb said in a recent interview the agency is seeking an approval pathway for legitimate stem cell therapies “that’s not overly burdensome.”

“The regenerative medicine space has been a tough road clinically and Athersys is one of the bright, shining stars,” said Steven Martin, managing member of Chicago-based Aspire Capital and a long-time holder of Athersys shares.

Athersys believes Multistem - 1.2 billion cells delivered via simple intravenous drip - dampens the immune system’s hyper-inflammatory reaction to signals that the brain is under attack during stroke, and promotes healing.

The body’s reaction to stroke may also severely deplete the immune system, leading to later complications beyond paralysis or speech impairment. In the Phase II trial, Multistem patients had significantly fewer incidents of pneumonia, acute pulmonary distress and other serious complications.

That trial, attempting to extend the treatment window to 48 hours, failed. But researchers were encouraged by patients treated up to 36 hours post stroke.

“It’s reason to be cautiously optimistic,” said Dr. Ken Uchino, a leading Multistem investigator from Cleveland Clinic.

The company plans to begin a 300-patient Phase III study of Multistem in early 2018, aiming for U.S. and European approval after regulators agreed to protocols for one pivotal trial.

“This reinforces and cements an efficient path forward for us,” Athersys Chief Executive Gil Van Bokkelen said. A separate 220-patient Multistem trial in Japan for that market began enrolling patients through partner Healios KK.

“Of the many entities in this field, they have been careful and deliberate in their movement forward” and do not engage in “overwrought claims,” said Dr. S. Thomas Carmichael, co-director of UCLA Broad Stem Cell Center, who was not involved in Multistem trials.

Mesoblast’s MPC-150-IM therapy aims to mitigate advanced heart failure, a progressive condition in which the heart cannot pump enough blood to efficiently serve the body.

The company believes the therapy reduces inflammation, increases blood flow and spurs blood vessel formation that helps repair the heart muscle. A single dose consists of 150 million highly purified stem cells delivered directly to the heart’s left ventricle by injection or catheter.

An ongoing Phase III trial of 600 advanced heart failure patients is currently enrolling. Reducing the severity of a patient’s heart failure “would give them back potentially many years of good quality life,” said Mesoblast CEO Silviu Itescu.

Independent monitors who oversee and can halt blinded clinical trials for futility gave a green light to continue the Mesoblast study in April after a review of the first 270 treated patients, suggesting the therapy might be effective.

A separate U.S. National Institutes of Health-sponsored Phase II study of 159 end-stage heart failure patients dependent on an implanted pumping assist device completed enrollment in September, with results expected in the first quarter of 2018.

Some 250,000 people in the United States alone have been diagnosed with most serious class IV heart failure, and only about 9,000 receive a transplant or left ventricular assist device (LVAD) each year, Itescu said.

If such patients can recover enough to again rely on their own heart, said Dr. Joseph Woo, a heart surgeon at Stanford University and an investigator of the NIH trial, “this would be considered one of the big advances of this century.”

Editing by Michele Gershberg and Edward Tobin

Our Standards:The Thomson Reuters Trust Principles.

Athersys partner enrolls first patient in Japan in Treasure MultiStem study ...

Reply to robotinvestor - Msg #1038 - 11/15/2017 10:14

Athersys partner enrolls first patient in Japan in Treasure MultiStem study Athersys announced that its partner, HEALIOS K.K., has enrolled the first patient in its study in Japan evaluating MultiStem cell therapy treatment of patients who have suffered an ischemic stroke.The TREASURE study is designed to enroll a total of 220 patients with moderate to severe strokes and will be randomized 1:1, with patients receiving a single intravenous infusion of MultiStem or placebo within 18 to 36 hours of the onset of the stroke. The primary efficacy outcome is the proportion of subjects achieving an Excellent Outcome at three months following treatment. Excellent Outcome is a commonly used measure of efficacy in stroke treatment, evaluated using three standard clinical rating scales of functional and neurological deficit and recovery following the stroke, including the NIH Stroke Scale, modified Rankin Scale and Barthel Index. In parallel with the TREASURE trial, Athersys has been planning for its Phase 3 study entitled, MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2, to be conducted in North America and Europe. The MASTERS-2 study has received authorization from the U.S. FDA under a Special Protocol Assessment for the design and planned analysis of this pivotal clinical trial. The SPA provides formal agreement from the FDA that the protocol design, clinical endpoints, planned conduct and statistical analyses in this Phase 3 study are acceptable to support a regulatory submission for marketing approval of MultiStem cell therapy as a product for treating ischemic stroke patients. Additionally, the MultiStem stroke program has been awarded Fast Track designation by the FDA, meaning that the program is eligible for accelerated approval, priority review and rolling submission of the biologics license application, which facilitates a timely regulatory review. Recently, in addition to the SPA and Fast Track designations from the FDA, the MASTERS-2 trial also obtained a Final Scientific Advice positive opinion from the European Medicines Agency, and received the Regenerative Medicine Advanced Therapy designation from the FDA, which was established this year under the 21st Century Cures Legislation. The MASTERS-2 clinical trial is planned to be a randomized, double-blind, placebo-controlled clinical trial designed to enroll 300 patients in North America and Europe who have suffered moderate to moderate-severe ischemic stroke.
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser blacksheep: Reward | Watch | IgnoreATHX: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ATHX

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.